The therapeutic potential of nivolumab (PD-1 inhibitor) was examined in the CA209-003 Phase I study in multiple cancer types, which consisted of 122 patients with NSCLC, and has resulted in RR of 17%, 5-year OS rate of 16%, and a median response of 17 months [117]. Here, RPL17 is linked to cancer.